#0457

Aquablation for Benign Prostatic Hyperplasia: Evaluating Efficacy, Safety, and the Learning Curve in a Taiwanese Cohort

H. Ko¹, M. Tung¹, Y. Lin^1,2, C. Hsu¹, Y. Ou¹, P. Tsai³

¹Tung's taichung metroharbor hospital, Department of Urology, Taichung City, Taiwan
²National Chung Hsing University, Doctoral Program in Translational Medicine, Taichung City, Taiwan
³Tung's taichung metroharbor hospital, Department of Medical Statistics, Taichung City, Taiwan

Introduction:

Aquablation is a waterjet ablation therapy for benign prostatic hyperplasia (BPH) that has gained increasing attention. While its efficacy, durability, and safety have been demonstrated across various prostate sizes (30–150 mL), local data in Taiwan remain limited. This study presents our initial experience with 50 patients who underwent Aquablation.

Material and methods:

We retrospectively reviewed 50 consecutive patients who underwent Aquablation between March 2024 and February 2025, divided into Group I (first 25 cases) and Group II (subsequent 25 cases). Parameters assessed included IPSS, QoL, uroflowmetry (voiding volume, Qmax, Qmean, PVR), operative time, hemoglobin drop, Clavien-Dindo grade ≥2 complications, hospital stay, and catheter duration.

Results:

Group II patients were younger and had smaller prostates. Aquablation was successful in all cases. IPSS, QoL, Qmax, Qmean, and voiding volume improved significantly and were sustained at 3 months. PVR improved significantly only in Group I. Operative time was shorter in Group II, while hemoglobin drop was greater in Group I. Complications, hospital stay, and catheter duration were comparable.